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ABSTRACT  32 
Background Standard nasopharyngeal swab testing for SARS-CoV-2 detection by PCR is not 33 
always feasible due to limitations in trained personnel, personal protective equipment, swabs, 34 
PCR reagents, and access to cold chain and biosafety hoods. 35 
Methods We piloted the collection of nasal mid-turbinate swabs amenable to self-testing, 36 
including both standard polyester flocked swabs as well as 3D printed plastic lattice swabs, 37 
placed into either viral transport media or an RNA stabilization agent. Quantitative SARS-CoV-2 38 
viral detection by RT-qPCR was compared to that obtained by nasopharyngeal sampling as the 39 
reference standard. Pooling specimens in the lab versus pooling swabs at the point of collection 40 
was also evaluated. 41 
Results Among 275 participants, flocked nasal swabs identified 104/121 individuals who were 42 
PCR-positive for SARS-CoV-2 by nasopharyngeal sampling (sensitivity 87%, 95% CI 79-92%), 43 
mostly missing those with low viral load (<10^3 viral copies/uL). 3D-printed nasal swabs 44 
showed similar sensitivity. When nasal swabs were placed directly into an RNA stabilizer, the 45 
mean 1.4 log decrease in viral copies/uL compared to nasopharyngeal samples was reduced to 46 
<1 log, even when samples were left at room temperature for up to 7 days. Pooling sample 47 
specimens or swabs both successfully detected samples >102 viral copies/uL.  48 
Conclusions Nasal swabs are likely adequate for clinical diagnosis of acute infections to help 49 
expand testing capacity in resource-constrained settings. When collected into an RNA 50 
preservative that also inactivates infectious virus, nasal swabs yielded quantitative viral loads 51 
approximating those obtained by nasopharyngeal sampling.  52 
 53 
BACKGROUND  54 
Since the start of the SARS-CoV-2 pandemic, testing has been a cornerstone of the public health 55 
response. The de facto standard for clinical testing is PCR from nasopharyngeal (NP) swabs. 56 
However, nasopharyngeal sampling must be performed by trained staff using personal 57 
protective equipment (PPE). Shortages in both, as well as NP swabs themselves, often manifest 58 
when case counts climb. A wide array of strategies amenable to self-collection have been 59 
piloted to expand testing capacity, including the collection of nasal swabs, oropharyngeal and 60 
tongue swabs, saliva, and oral rinses (1–3). The volume of tests conducted can also become 61 
burdensome and lengthen turnaround time, spurring interest in pooled testing strategies in low 62 
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prevalence and settings (4–8). Finally, regarding sample storage and transport, viral specimens 63 
are typically placed in viral transport medium, and CDC recommends maintenance of cold chain 64 
prior to processing (1), but this may not be possible in all settings.  65 
In order to implement a household transmission study in the early phases of the epidemic in 66 
North Carolina, when shortages of PPE and swabs were prevalent, we adopted a strategy of 67 
self-collected nasal swabs from household members during follow-up. Here we compare this 68 
strategy to concurrently collected nasopharyngeal swabs at enrollment in our study population. 69 
We piloted different types of swabs stored in different media. Given interest in pooling 70 
strategies for high throughput testing, we also used our cohort to test two different pooling 71 
strategies: pooling swabs at the point of collection or pooling sample lysate in the lab. Our 72 
findings provide confidence in using self-collected nasal swabs, preferably stored in an RNA 73 
stabilizer, when nasopharyngeal sampling is not feasible. 74 
 75 
METHODS 76 
Clinical samples  77 
Clinical samples were collected as part of a SARS-CoV-2 household transmission study 78 
conducted in the Piedmont region of North Carolina. The study received ethical approval from 79 
the Institutional Review Board  at the University of North Carolina-Chapel Hill and is registered 80 
at clinicaltrials.gov (NCT04445233). Participants were enrolled if they were adults that tested 81 
positive for SARS-CoV-2 by PCR at the UNC Respiratory Diagnostic Center and shared a living 82 
space with one or more persons who also agreed to participate. At enrollment, a standard 83 
clinician-collected nasopharyngeal (NP) swab was performed, followed by up to two other nasal 84 
swabs (on different sides) that were either collected by study staff or self-collected by the 85 
participant or their guardian with guidance from study staff (Figure S1). For nasal sampling, 86 
participants were instructed to insert the swab about 1-2 inches into one nostril , then swirl 5 87 
times while slowly withdrawing the swab before placing it into the collection tube. All samples 88 
were placed into a cooler on ice prior to processing in a BSL2+ laboratory space.  89 
-  90 
Sample collection strategies  91 
Flocked NP swabs were collected into 3mL of Becton Dickinson’s co-packaged universal viral 92 
transport system. Two types of nasal swabs designed for mid-turbinate sampling (NMT) were 93 
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used: flocked NMT swabs (COPAN, Murrietta CA) and 3D-printed lattice NMT swabs (Resolution 94 
Medical, Fridley MN) (Figures S1). Both were collected into 3mL viral transport media (VTM) 95 
prepared using CDC SOP# DSR-052-05. Upon sample receipt in the laboratory, 1mL of the 96 
collected sample was combined with 1mL 2X DNA/RNA Shield, a nucleic acid preservation agent 97 
and lysis buffer (Zymo Research), and stored at -80°C until extraction. RNA was extracted from 98 
200uL of the lysate using the Quick-RNA Viral 96 Kit (Zymo Research) and eluted in 20uL of 99 
water. We also evaluated the effect of storage media by collecting flocked NMT swabs directly 100 
into 3mL of 1X DNA/RNA Shield (Shield), with aliquots either frozen immediately upon return to 101 
the lab or left at room temperature for 4 or 7 days before being stored at -80°C. RNA was 102 
extracted from 100 uL of the lysate using the same extraction and elution protocols.  103 
 104 
qRT-PCR viral quantification  105 
Samples were tested using a CDC RT-qPCR protocol authorized for emergency use that consists 106 
of three unique assays: two targeting regions of the virus’ nucleocapsid gene (N1, N2) and one 107 
targeting human RNase P gene (RP) (Catalog # 2019-nCoVEUA-01, Integrated DNA 108 
Technologies) (9). 5uL of extracted RNA was added to 15uL of each assay’s reaction mixture 109 
containing TaqPath 1-Step RT-qPCR Master Mix, CG (Thermofisher Scientific) and the 110 
corresponding primer-probe set (IDT), followed by the recommended thermocycler protocol. 111 
Plasmid DNA containing the human RPP30 gene and SARS-CoV-2 in vitro transcribed RNA 112 
control (nCoVPC, IDT) were used as positive controls. Water was used as a negative extraction 113 
control. Samples were designated positive if all three PCRs were positive (N1 and N2 for virus, 114 
RP for adequate sampling). If the N1 and N2 PCRs were negative, but the RP assay had a Ct 115 
value ≥30 or was negative, suggesting inadequate sampling, then the sample was re-extracted. 116 
The second result was reported if the RP Ct value was <30 or if both N1 and N2 PCRs were 117 
positive regardless of RP Ct value. 118 
The viral load of each sample, in copies/uL, was extrapolated from standard curves generated 119 
for each viral assay (N1 and N2) using serial dilutions of nCoVPC (2 to 100,000 viral RNA 120 
copies/uL). The average copies/uL between the N1 and N2 assays was used as the final 121 
quantitative viral load. Based on the sample collection and RNA extraction volumes as well as 122 
volume of template RNA used in the RT-qPCR (5uL), this viral load represents the number of 123 
viral RNA copies per 5 uL of VTM or Shield sample. 124 
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Pooling strategies  125 
The efficacy of pooling NMT samples was examined through two different approaches: pooling 126 
swabs at the point of care into the same collection vessel and pooling individual sample lysates 127 
prior to extraction. For the first strategy, self-collected 3D-printed lattice NMT swabs from each 128 
member of a household of three or more were collected and pooled together in 5mL of VTM. 129 
This was done at one or more of the study visits for each household. 200uL of the sample lysate 130 
was extracted and quantified as above. Results were compared to the self-collected individual 131 
flocked NMT swab collected at the same visit. In the second pooling strategy, one qRT-PCR 132 
positive sample lysate from a flocked NMT swab (pre-RNA extraction) was pooled with sample 133 
lysate from negative individuals to construct pool sizes of 5, 10, 15, and 20. The Ct values of 134 
twelve samples with viral copies/uL ranging from 101 to 107 were compared to the Ct values of 135 
their corresponding pools. 136 
 137 
Statistical analysis   138 
A probit analysis of results from the nCoVPC plasmid control concentrations (ranging from 2 to 139 
100,000 copies/uL as part of standard curves generated in every RT-qPCR run) by parametric 140 
curve fitting to hit rate data was used to determine the limit of detection (LOD) of the N1 and 141 
N2 qRT-PCR assays. Samples that were positive in both N1 and N2 assays, but with an average 142 
viral load that fell below the LOD were categorized as indeterminate. The sensitivity and 143 
specificity of different swab types for RT-qPCR detection of SARS-CoV-2 was calculated using 144 
flocked NP swabs as the reference standard. Additionally, the difference in the quantitative 145 
viral load was compared for different collection strategies. Comparisons were made on the log 146 
scale and analyzed using Wilcoxon matched-pairs signed rank testing with a p-value<0.05 147 
considered significant. Statistical analyses were performed using GraphPad Prism 8 and SAS 9.4 148 
(Cary, NC).  149 
 150 
RESULTS  151 
We report data from 644 swab samples collected from 275 participants (91 households) at 152 
enrollment, 24 pools collected at follow-up or enrollment, and 44 pools constructed from 153 
participant samples in the lab. Participants ranged in age from 1-77 years old, with 71% >18 154 
years of age.  155 
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Limit of detection of RT-qPCR assay  156 
Probit analysis of nCoVPC plasmid control concentrations tested in 33 RT-qPCR runs yielded a 157 
limit of detection (LOD) for the N1 and N2 assays of 9 and 13 copies/uL, respectively (Table S1). 158 
The average LOD between the two assays, 11 copies/uL, was used as the cutoff for sample 159 
positivity. A sample was deemed positive if the average viral load derived from the cycle 160 
threshold (Ct) values of N1 and N2 corresponded to a concentration  ≥11 copies/uL, 161 
indeterminate if  <11 copies/uL, and negative if either assay failed to amplify. Altogether, 162 
21/702 (3.0%) samples tested fell into the indeterminate category.  Another 33 (4.7%) samples 163 
only amplified in one assay (N1 or N2 assay), but with a Ct value corresponding to a viral load 164 
that fell below the LOD. Only 2 samples (0.3%) were discordant between the N1 and N2 assays 165 
(positive in one but not the other).  166 
 167 
Comparison of collection swabs and storage medium  168 
Compared to 169 
nasopharyngeal sampling, 170 
flocked nasal mid-171 
turbinate (NMT) swabs 172 
displayed slightly 173 
decreased sensitivity, but 174 
were well-accepted by the 175 
participants and yielded 176 
adequate sampling. 177 
Altogether, at enrollment, 178 
275 study participants 179 
completed 226 NP swabs 180 
and 418 NMT swabs (255 181 
flocked and 51 3D-printed 182 
in VTM, 112 flocked in 183 
Shield) (Figure S1). Of the 184 
49 participants that 185 
declined to do NP swabs, 186 
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46 agreed to at least one type of NMT swab. Inadequate sampling, as defined by negative N1 187 
and N2 PCRs in concert with a negative human RP PCR or Ct ≥30, occurred in small numbers of 188 
flocked 189 
swabs, but a 190 
substantial 191 
proportion of 192 
3D-printed 193 
plastic lattice 194 
swabs: 1/226 195 
(0.4%) of NP 196 
swabs, 197 
14/343 (4.1%) 198 
of flocked 199 
NMT swabs, 200 
and 11/51 201 
(21.6%) of 202 
3D-printed 203 
plastic lattice 204 
swabs.  205 
 206 
Using NP 207 
swabs as the 208 
reference 209 
standard, 210 
flocked NMT 211 
swabs 212 
showed excellent specificity (98%, 95% CI 90-100%) but slightly decreased sensitivity (87%, 95% 213 
CI 79-92%) for SARS-CoV-2 detection by RT-qPCR (Figures 1&2). Of 173 NP-NMT swab pairs, 104 214 
were both positive, 52 both negative, and 10% (17/173) were discordant. Three of these 215 
discordances were likely due to inadequate sampling (1 NP, 2 NMT swabs with RP Ct value ≥30), 216 
while 71% of the rest (10/14) occurred in samples with low viral loads (<103 viral copies 217 
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 8 
detected in the NP swab). In the 104 positive swab pairs, NMT samples displayed lower average 218 
viral loads (Spearman correlation coefficient=0.67, Figure 1), with a mean 1.3 log decrease in 219 
viral copies/uL (IQR 0.6 - 2.1 log viral copies/ul) compared to NP sampling (p<0.0001) (Figure 220 
3A). This was at least partly due to a sampling difference, as NMT swabs also showed on 221 
average 3.1 cycles higher Ct values in the human RP PCR (Figure S2).  222 
 223 
Though the 224 
3D-printed 225 
plastic 226 
lattice NMT 227 
swabs were 228 
more likely 229 







viral loads 237 
similar to 238 
flocked 239 
NMT swabs 240 
(Figure 3A). This was true despite on average 1.2 higher Ct values for the human RP assay in the 241 
3D vs. flocked swabs. Compared to NP sampling, 3D-printed NMT swabs displayed 95.7% 242 
sensitivity (95% CI 78.1%-99.9%) and 100% specificity (95% CI 63.1-100%) among 48 swab pairs 243 
(Figure 2). 244 
   245 
Placing flocked NMT swabs directly into 1x DNA/RNA Shield did not improve the sensitivity of 246 
detection, but did result in viral loads comparable to those obtained by NP sampling. Aliquots 247 
of Shield samples were either directly stored at -80C (similar to other samples collected on day 248 
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1), or left out at room temperature for 4 or 7 days prior to freezing and processing. All NMT 249 
Shield samples showed a specificity of 100% compared to NP swabs, while sensitivity ranged 250 
86%, 78%, and 91%  for the samples frozen at day 1, 4, and 7, respectively (Figure 2).  251 
Altogether, regardless of how many days the Shield samples were left out, the overall 252 
sensitivity was 85% (95% CI 77-92%). While sensitivity for detection was slightly diminished, 253 
quantitative viral loads derived from NMT Shield aliquots frozen on day 1 were comparable to 254 
NP viral loads (mean decrease of 0.5 log viral copies/uL (IQR -0.3-1.4), p=0.09) (Figure 3B). For 255 
aliquots left at room temperature until day 4 and day 7, we observed a mean decrease that was 256 
still <1 log viral copies/uL compared to NP sampling (mean 0.8 and 0.8 log viral copies/ul, 257 
respectively (p=0.001 and p=0.0002) (Figure 3B). 258 
 259 
Pooling strategies   260 
The pooling strategies 261 
implemented were sufficient 262 
for detecting samples with 263 
viral loads >10^2 copies/uL 264 
but were not as sensitive as 265 
individual swabs for detecting 266 
samples with lower viral loads. 267 
Of the 24 pools of 3D-NMT 268 
swabs pooled at the point of 269 
care, 3 were indeterminate, 270 
and 2 (8%) yielded discordant 271 
results (depicted as red stars 272 
in Figure 4). Under the 273 
assumption that the 274 
concurrently collected 275 
individual flocked NMT swabs 276 
were accurate, the two 277 
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discordant results were false 278 
negative pools where the 279 
individual swab had a viral 280 
load  <100 copies/uL, close to 281 
the limit of detection (Table 282 
S2). Of the 22 concordant 283 
pools, 8 were negative and 11 284 
were positive, mostly with 285 
individual swab viral loads 286 
≥10^2 copies/uL.  287 
 288 
Similarly, when individual 289 
sample lysates were pooled 290 
in the lab at varying pool 291 
sizes, none of the 2 sets of experimental pools containing a sample with a viral load of 10^1 292 
copies/uL were positive (Figure 5). Of the 3 sets of pools containing a sample with a viral load of 293 
10^2 copies/uL, 2 were positive at every pool size, while the remaining set was positive within 294 
pools of 5 and 10 samples, but indeterminate when the pool size was increased to 15 and 20 295 
samples. The remaining pools constructed with samples with a viral load >10^2 copies/uL were 296 
positive across all pool sizes. The average total Ct value increase for the pools that remained 297 
positive at a pool size of 20 samples was 5.1 cycles, close to the expected 4.3 cycle increase for 298 
a sample diluted 1:20 using a PCR with 100% amplification efficiency. 299 
 300 
DISCUSSION   301 
In a highly exposed outpatient cohort, we found nasal swabs to be reasonably  sensitive, 302 
capturing 87% of SARS-CoV-2 infections diagnosed by nasopharyngeal sampling. This estimate 303 
is similar to most other outpatient studies showing >85% concordance between self-collected 304 
nasal swabs (either nasal mid-turbinate or anterior nasal swabs) and clinician-collected 305 
nasopharyngeal sampling (2,10–13). Not all studies are consistent however, likely due to 306 
heterogeneity in testing environments, and inclusion of non-acute samples collected during 307 
follow-up (14,15). 308 
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By calculating quantitative SARS-CoV-2 viral loads, our study gives clarity on where sensitivity is 309 
diminished (16). For the majority of participants in which nasal sampling failed to detect virus, 310 
the NP viral load was <1000 copies/uL, at a level that is likely non-infectious. Of these 311 
participants, 7/11 were antibody-positive at the time of sampling (unpublished data), and for 312 
the 8/11 participants still reporting symptoms, the average duration of reported symptoms was 313 
6.5 days. Thus nasal samples are likely adequate for clinical diagnosis of acute infections to help 314 
expand testing capacity, but insensitivity to low viral load infections should be taken into 315 
consideration. On average, the decreased sensitivity of NMT swabs led to a little over a log 316 
decrease in viral copies/uL compared to NP swabs.  317 
 318 
Our pragmatic approach of “show one, then do one” meant that nasal swabs were both 319 
clinician and self-collected. Also, since we often collected two nasal swabs per person, one from 320 
each nostril, our sampling strategy may have slightly underperformed relative to other studies 321 
that sample both nostrils with the same swab. It should be noted that we tested flocked and 322 
3D-printed lattice swabs, but did not test dry swabs or non-flocked cotton swabs. Where high 323 
quality swabs are not available, but other swab types are plentiful, a strategy of combining oral 324 
and nasal samples appears promising (17).  325 
 326 
3D-printed plastic swabs may also help address supply chain shortages (18,19). We first 327 
acquired prototype NMT lattice swabs from Resolution Medical in anticipation of shortage of 328 
supplies for our research study. In our limited testing, the prototype 3D-printed NMT lattice 329 
swabs showed high categorical concordance with NP swabs and also yielded similar viral loads 330 
compared to flocked NMT swabs. Similar high concordance has been demonstrated for 3D-331 
printed nasopharyngeal swabs (18–20). Anecdotally, the prototype 3D-printed were observed 332 
to be more uncomfortable for study participants compared to flocked NMT swabs, a sentiment 333 
shared by other studies (18). This may have contributed to the higher proportion of samples 334 
deemed as inadequate sampling.  335 
  336 
Labs also face VTM shortages requiring alternate transport media (21,22). Reagents which can 337 
inactivate virus and also keep samples stable at ambient temperature may be particularly apt 338 
substitutes (23). We used 1xDNA/RNA shield (Zymogen), an RNA preservation agent that has 339 
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been widely used to inactivate SARS-CoV-2 and other respiratory viruses in various sample 340 
types and is now part of saliva and NMT Shield collection kits that have received FDA 341 
emergency use authorization (24–26). In our hands, storage of nasal swab samples in Shield did 342 
not improve their overall diagnostic sensitivity, but positive NMT swabs stored in Shield 343 
maintained  quantitative viral loads more similar to those detected in concurrently collected NP 344 
swabs.  345 
 346 
Pooling specimens in the lab is a well-documented strategy to accelerate SARS-CoV-2 testing in 347 
high-throughput settings (4–6). As in previous studies, we found that although Ct values do 348 
increase with pooling, the strategy can be broadly successful (27–31). Samples with viral loads 349 
at or near the limit of detection (31), or <103 viral copies/uL in the CDC EUA assay we adopted, 350 
may go undetected as pool sizes increase. This was even more apparent when pooling swabs at 351 
the point of collection, which we piloted as unsupervised self-collection of 3D-printed swabs 352 
into the same conical tube containing 5mL of VTM.   353 
 354 
Our findings add to the evidence base for nasal swabs as an adequate substitute for PCR-based 355 
clinical diagnosis of SARS-CoV-2 infection in outpatient settings where nasopharyngeal sampling 356 
is challenging. Viral recovery can be maintained even when immediate cold chain is not possible 357 
by storing swabs in an RNA preservation agent that also deactivates infectious virus. Combined 358 
with pooling specimens in the lab, these practical strategies can help expand testing in 359 
resource-constrained settings.  360 
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 475 
FIGURE LEGENDS 476 
Figure 1. Concordance and comparison of SARS-CoV-2 viral loads from paired nasopharyngeal 477 
(NP) and nasal mid-turbinate (NMT) swabs. Paired NP and NMT swabs from 173 participants 478 
showed overall good concordance, with most discordances (15/16) arising from positive 479 
NP/negative NMT samples. Quantitative viral loads derived from the average of N1 and N2 qRT-480 
PCR assays favored NP swabs compared to NMT swabs. A y=x dashed line is drawn for 481 
reference. 482 
 483 
Figure 2. Concordance of SARS-CoV-2 RT-qPCR detection between nasopharyngeal (NP) swabs 484 
and two different nasal mid-turbinate (NMT) swab types, stored in viral transport media 485 
(VTM) or 1x DNA/RNA shield (Shield). In (A), sensitivity and specificity of standard flocked 486 
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(NMT) or 3D-printed (3D) nasal swabs collected into VTM are shown using NP swabs with co-487 
packaged universal viral transport system as the reference standard. Concordance of flocked vs. 488 
3D nasal swabs is also shown. In (B), flocked NMT swabs were stored in Shield, and sample 489 
aliquots were directly frozen on day 1 (D1) or kept at room temperature before being stored at 490 
-80C on day 4 (D4) or day 7 (D7). Note that samples with indeterminate viral load (<11 491 
copies/ul) were not included in the sensitivity/specificity analyses. 492 
 493 
Figure 3. Comparison of SARS-CoV-2 viral loads between standard NP swabs and NMT or 3D 494 
NMT swabs (A) as well as NMT swabs collected into 1x DNA/RNA Shield and stored for 495 
different intervals (B). The distribution of the difference in log viral load is depicted for each 496 
comparison. Median log-fold changes are indicated by a solid line with interquartile values 497 
indicated by dotted lines. The number of sample pairs is indicated for each comparison.  498 
 499 
Figure 4. Comparison of Ct values from nasal mid-turbinate (NMT) swabs pooled from 500 
households of 3-5 persons at the point of care vs. concurrently collected individual NMT 501 
swabs. Among the pools collected from 24 households (listed along the x axis in order of 502 
decreasing viral loads), 2 pools with discordant results from individual swabs are depicted as 503 
red stars. Viral loads derived from the Ct values for each sample and the corresponding pool are 504 
found in Table S2.  505 
 506 
Figure 5. Ct values of increasing pool sizes constructed containing a single positive sample 507 
with varying viral loads. Viral transport media from a single positive sample with a viral load 508 
ranging from 101 to 107 were used to construct pool sizes of 5, 10, 15, 509 
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